A Primer of Quasi-Exact Tests for Randomized Clinical Trials with Binary Endpoints
For planned clinical trials with a binary endpoint, standard statistical tests can be very inaccurate in their error control, especially when the trial is unbalanced. Specifically, Type 1 error can greatly exceed a nominal target like 5%, even for quite large sample sizes, and power can be much less than a nominal target such as 80%. Confidence limits may not have the correct coverage. The purpose of this article is first to give clinical trialists an appreciation of this fact. We then describe well-studied alternatives to the standard methods, which are simple in conception but can be quite challenging to implement. These contemporary methods in frequentist statistical theory, known as quasi-exact methods, have been neglected in medical applications. We provide an R-package that can be used to provide accurate inference results based on our recommended quasi-exact test. The package will also calculate the exact size and power of the test, once the control and treatment samples sizes are finalized. All proposals are illustrated with a real-world example on the treatment of prostate cancer. We would recommend practitioners to use quasi-exact methods in the analysis of randomized clinical trials.
Authors
- Chris J. Lloyd (ORCID: https://orcid.org/0000-0001-5745-1951)
- Enrico Ripamonti (ORCID: https://orcid.org/0000-0002-0584-8401)
Institutions
- The University of Melbourne (AU)
- Brescia University (US)
- Center for Neurosciences (US)
- University of Brescia (IT)
Publication Details
- Journal
- Statistics in Biopharmaceutical Research
- Published
- 2024-09-10
- DOI
- https://doi.org/10.1080/19466315.2024.2402899
- Primary Topic
- Statistical Methods in Clinical Trials
- Type
- article
- Field-Weighted Citation Impact
- 0.00